A 28-amino-acid peptide naturally produced by the thymus gland that plays a central role in immune system maturation and function. Approved in 35+ countries for hepatitis B and as an immune adjuvant. Used globally as an immune modulator in viral infections and cancer.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. The thymus gland is the organ where T-cells — the adaptive immune system's primary effector cells — mature and develop the ability to distinguish self from non-self. Tα1 is one of the key peptides produced by the thymus that orchestrates this maturation process, and its decline with age (thymic involution) is believed to contribute to the immune deterioration seen in older adults.
Marketed as Zadaxin (thymalfasin), Tα1 is approved in over 35 countries — including China, Italy, and many Asian and Latin American nations — for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. Remarkably, it is not approved in the United States, despite extensive international clinical use spanning three decades. An orphan drug designation was granted by the FDA, but the sponsoring company did not pursue full NDA approval — a commercial decision rather than a safety or efficacy concern. This creates an unusual situation where a peptide with Level I clinical evidence and regulatory approval across dozens of countries remains formally unapproved in the largest pharmaceutical market.
Tα1 gained renewed global attention during the COVID-19 pandemic, when it was deployed in China and Italy as an immune support therapy for critically ill patients, particularly those with lymphopenia (dangerously low T-cell counts). Retrospective studies from Wuhan showed reduced mortality in lymphopenic COVID patients treated with Tα1, though these were observational studies, not randomized trials.
In the United States, Tα1's status changed in late 2023 when the FDA placed it on the Category 2 restricted list, prohibiting compounding pharmacies from preparing it. In February 2026, HHS Secretary Kennedy announced that Tα1 is among the approximately 14 peptides expected to return to Category 1 status — restoring legal compounding access under physician prescription. For the full regulatory timeline, see our March 2026 briefing.
Tα1 is an immune modulator — a critical distinction from immune stimulants. Rather than simply boosting immune activity (which could be harmful in autoimmune conditions or cytokine storm scenarios), Tα1 calibrates the immune response: it upregulates underactive immunity and dampens overactive inflammatory responses. This bidirectional regulation is what makes it therapeutically versatile across infections, cancer, and hyperinflammatory states.
Tα1 activates the innate immune system by binding to Toll-like receptors 2 and 9 (TLR2/TLR9) on dendritic cells. TLRs are pattern-recognition receptors that detect pathogen-associated molecular patterns. Tα1 binding stimulates dendritic cell maturation, enhancing their antigen-presenting capacity — the ability to "show" pieces of pathogens to T-cells and trigger an adaptive immune response. Mature dendritic cells produce key cytokines including IL-12 and IFN-α, which promote Th1 polarization (the arm of adaptive immunity most effective against intracellular pathogens and tumors).
Tα1 directly promotes the maturation of immature thymocytes into functional T-cells, including both CD4+ helper T-cells and CD8+ cytotoxic T-cells. This is particularly valuable in immunocompromised patients — the elderly, cancer patients undergoing chemotherapy, and those with HIV or other conditions that deplete T-cell populations. By restoring T-cell numbers and function, Tα1 rebuilds the immune surveillance capacity that these patients have lost.
Additionally, Tα1 enhances natural killer (NK) cell cytotoxicity. NK cells are innate immune cells that kill virus-infected and tumor cells without requiring prior antigen presentation. The combined enhancement of NK cells (immediate, non-specific killing) and T-cells (targeted, antigen-specific killing) provides broad-spectrum immune support.
In hyperinflammatory states — such as sepsis, severe COVID-19, or cytokine release syndrome — Tα1 has been shown to reduce levels of pro-inflammatory cytokines including IL-6 and TNF-α. This anti-inflammatory capacity, operating alongside its immune-enhancing effects, is what allows Tα1 to be used in critically ill patients where excessive inflammation is part of the pathology. The mechanism appears to involve modulation of the Th1/Th2 balance and suppression of NF-κB-driven inflammatory cascades.
| Pathway | Effect | Significance |
|---|---|---|
| TLR2/TLR9 activation | Stimulates dendritic cell maturation and cytokine production | Bridges innate and adaptive immunity |
| T-cell maturation | Promotes differentiation of immature thymocytes into functional CD4+ and CD8+ T-cells | Restores T-cell populations in immunocompromised patients |
| NK cell enhancement | Increases NK cell cytotoxicity | Improves innate killing of virus-infected and tumor cells |
| Cytokine modulation | Increases IFN-α, IL-2, IL-12; balances Th1/Th2 response | Promotes antiviral and antitumor immunity without excessive inflammation |
| Anti-inflammatory | Reduces IL-6, TNF-α in hyperinflammatory states | May prevent cytokine storm in severe infections |
Tα1 has one of the strongest clinical evidence profiles among non-FDA-approved peptides. Its evidence base includes multiple randomized controlled trials, meta-analyses, and over three decades of real-world clinical use in 35+ countries. This distinguishes it sharply from peptides like BPC-157, where the evidence is almost entirely preclinical.
The hepatitis B evidence is the foundation of Tα1's regulatory approvals internationally. Multiple RCTs and meta-analyses have demonstrated that Tα1, when combined with interferon therapy, significantly improves viral clearance rates and HBsAg seroconversion compared to interferon alone. These results were robust enough to support marketing approval across dozens of countries and are the primary basis for Zadaxin's commercial success in Asia.
Tα1 has been studied as an immune adjuvant in cancer treatment — not as a standalone anticancer agent, but as a complement to chemotherapy and radiation that helps preserve and restore immune function during treatment. Clinical trials in hepatocellular carcinoma (HCC), melanoma, and non-small cell lung cancer have shown improvements in immune parameters (T-cell counts, NK cell activity) and, in some studies, improvements in overall survival when Tα1 was added to standard chemotherapy regimens. The evidence is strongest in HCC, where Tα1 is part of standard treatment protocols in several Asian countries.
During the COVID-19 pandemic, Tα1 was used extensively in China (where it was already commercially available as Zadaxin) for critically ill patients, particularly those with lymphopenia. Retrospective studies from Wuhan reported reduced mortality in lymphopenic patients treated with Tα1, and Italian hospitals also deployed it for severe cases. However, these studies were observational and retrospective — no large randomized controlled trial of Tα1 for COVID-19 has been completed. The rationale was sound (restoring T-cell function in patients whose T-cells were depleted by the virus), but the evidence level remains II-III.
| Indication | Design | Findings | Level |
|---|---|---|---|
| Hepatitis B | Multiple RCTs, meta-analyses | Improved viral clearance and seroconversion rates combined with interferon. Basis for approval in 35+ countries | Level I |
| Hepatitis C | RCTs | Enhanced sustained virological response when added to IFN + ribavirin triple therapy | Level I-II |
| Cancer adjuvant | Multiple trials (HCC, melanoma, NSCLC) | Improved immune parameters and survival when combined with chemotherapy; strongest data in HCC | Level I-II |
| COVID-19 | Retrospective, observational | Reduced mortality in lymphopenic critically ill patients in China and Italy | Level II-III |
| Vaccine adjuvant | Clinical studies | Enhanced antibody responses to influenza and hepatitis B vaccines in elderly and immunocompromised populations | Level II |
Tα1 has an exceptionally well-established safety profile — arguably the best of any non-FDA-approved peptide. Over 30 years of clinical use across 35+ countries, involving millions of patient exposures, have produced no reports of significant systemic adverse effects. This long track record of real-world safety data is unusual in the peptide space, where most compounds lack substantial human exposure data.
Injection site reactions: The most commonly reported adverse effect is mild, transient redness or swelling at the subcutaneous injection site, occurring in a small percentage of patients. These reactions are self-limiting and do not typically require treatment discontinuation.
No immunosuppression: Unlike many immune-modulating drugs (such as corticosteroids, calcineurin inhibitors, or biologics), Tα1 does not cause immunosuppression. It does not increase infection risk. This is a direct consequence of its modulatory rather than suppressive mechanism — it enhances immune function without creating the vulnerability that comes with broadly dampening the immune system.
No autoimmune exacerbation: Despite enhancing T-cell function, Tα1 has not been associated with triggering or worsening autoimmune conditions in clinical use. This may be related to its Th1/Th2 balancing properties, which prevent the kind of unchecked T-cell activation that drives autoimmune pathology. However, caution is still warranted in patients with active autoimmune disease, as formal studies in this population are limited.
Dosing: The standard clinical dose is 1.6 mg subcutaneously, typically administered twice weekly. This dosing regimen is based on the approved Zadaxin protocol and has the strongest safety data supporting it. Some clinicians use daily dosing for acute conditions (severe infections, peri-chemotherapy immune support), though this is less well-studied in controlled settings.
Tα1 occupies a unique regulatory position: widely approved and used internationally, but formally unapproved in the United States. The February 2026 HHS announcement is expected to change its U.S. accessibility significantly.
| Jurisdiction | Status |
|---|---|
| FDA (United States) | Not FDA-approved. Orphan drug designation was granted but full NDA was not pursued. Was placed on Category 2 restricted list in late 2023. Expected to return to Category 1 (legal for compounding under prescription) per February 2026 HHS announcement. Formal FDA guidance not yet published as of late March 2026. |
| International | Approved as Zadaxin (thymalfasin) in 35+ countries including China, Italy, Philippines, Thailand, Mexico, Argentina, and many others. Used clinically for hepatitis, cancer adjuvant therapy, and immune support. |
| WHO | Listed as an essential medicine in several countries |
| WADA | Not banned (legitimate medication with approved therapeutic use in many jurisdictions) |
The practical significance of Category 1 reclassification for Tα1 is substantial. Because Zadaxin is not marketed in the United States, American patients and clinicians have had no legal access route since the Category 2 restriction in 2023 (aside from grey-market research peptides). Restoration to Category 1 would allow licensed U.S. compounding pharmacies to prepare Tα1 with a valid prescription — using GMP-grade API sourced from qualified manufacturers. For supplier evaluation guidance, see the supplier evaluation guide on PeptideBond Reviews.